Based on the multivariate analysis of the entire cohort CTLA4 rs231775 was a relevant indicator of favorable treatment outcome in r/r DLBCL treated with anti-CD19 CAR-T cell therapy independent of disease status, age, sex, and type of CAR-T product applied. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.